Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141:1954–70. https://doi.org/10.1182/blood.2022017423
Article CAS PubMed Google Scholar
Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801–21. https://doi.org/10.1002/ajh.26857
Article CAS PubMed Google Scholar
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973–7. https://doi.org/10.1182/blood-2004-07-2864
Article CAS PubMed Google Scholar
Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. Published online August 21, 2015. https://doi.org/10.1038/leu.2015.233
Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2014;20:89–97. https://doi.org/10.1016/j.bbmt.2013.10.018
Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114:5264–70. https://doi.org/10.1182/blood-2009-07-234880
Article CAS PubMed Google Scholar
Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124:1183–91. https://doi.org/10.1182/blood-2014-04-572545
Article CAS PubMed PubMed Central Google Scholar
Hernández-Boluda JC, Pereira A, Alvarez-Larran A, Martín AA, Benzaquen A, Aguirre L, et al. Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of A New Prognostic Model. Biol Blood Marrow Transpl. 2020;26:2237–44. https://doi.org/10.1016/j.bbmt.2020.07.022
Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transpl. 2010;45:458–63. https://doi.org/10.1038/bmt.2009.188
Robin M, Espérou H, de Latour RP, Petropoulou AD, Xhaard A, Ribaud P, et al. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. Br J Haematol. 2010;150:721–4. https://doi.org/10.1111/j.1365-2141.2010.08276.x
Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152:331–9. https://doi.org/10.1111/j.1365-2141.2010.08417.x
Robin M, Porcher R, Orvain C, Bay JO, Barraco F, Huynh A, et al. Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transpl. 2021;56:1888–99. https://doi.org/10.1038/s41409-021-01252-7
Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35:3551–60. https://doi.org/10.1038/s41375-021-01276-4
Article CAS PubMed PubMed Central Google Scholar
Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, et al. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transpl. 2019;54:204–11. https://doi.org/10.1038/s41409-018-0226-1
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2016;22:1206–11. https://doi.org/10.1016/j.bbmt.2016.02.019
Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023;108:1900–8. https://doi.org/10.3324/haematol.2022.281958
Article CAS PubMed PubMed Central Google Scholar
Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, et al. Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis. Haematologica. Published online January 17, 2019. https://doi.org/10.3324/haematol.2018.201400
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233–42. https://doi.org/10.1182/blood-2018-12-890889
Article CAS PubMed Google Scholar
Jain T, Tsai HL, DeZern AE, Gondek LP, Elmariah H, Bolaños-Meade J, et al. Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis. Transpl Cell Ther. 2022;28:259.e1–259.e11. https://doi.org/10.1016/j.jtct.2022.02.004
Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36:856–64. https://doi.org/10.1038/s41375-021-01449-1
留言 (0)